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ABSTRACT 
 
Objective: To assess the additive value of fetal growth velocity between 32 and 36 weeks’ 
gestation on the performance of ultrasonographic estimated fetal weight (EFW) at 35+0 - 36+6 
weeks’ gestation for prediction of small for gestational age (SGA) neonates and adverse perinatal 
outcome. 
 
Methods: This was a prospective study of 14,497 singleton pregnancies that had undergone 
routine ultrasound examination at 28+0 - 34+6 and at 35+0 - 36+6 weeks’ gestation. Multivariable 
logistic regression analysis was used to determine whether addition of growth velocity, defined by 
a difference in EFW and abdominal circumference (AC) Z-scores between the early and late third 
trimester scans divided by the time interval between them, improved the performance of EFW at 
35+0 - 36+6 weeks in the prediction of first, delivery of SGA neonates with birthweight <10th and 
<3rd percentiles within two weeks and at any stage after assessment and second, composite of 
adverse perinatal outcome defined as stillbirth, neonatal death or admission to the neonatal unit 
for ≥48 hours. 
 
Results Multivariable logistic regression analysis demonstrated that significant contributors to 
prediction of SGA neonates were EFW Z-score at 35+0 - 36+6 weeks’ gestation, fetal growth 
velocity by either AC or EFW Z-scores and maternal risk factors. The area under the receiver 
operating characteristic curves (AUROC) and detection rate (DR) with 95% confidence interval, 
at 10% screen positive rate, for prediction of SGA neonates <10th percentile born within two weeks 
of assessment achieved by  EFW Z-score at 35+0 - 36+6 weeks (AUROC 0.938, 0.928 - 0.947; DR 
80.7, 77.6 - 83.9) were not significantly improved by addition of EFW growth velocity and maternal 
risk factors (AUROC 0.941, 0.932 - 0.950; p=0.061; DR 82.5, 79.4 - 85.3). Similar results were 
obtained when growth velocity was defined by AC rather than EFW growth velocity. Similarly, 
there was no significant improvement in AUROC and DR, at 10% screen positive rate, for 
prediction of SGA neonates <10th percentile born at any stage after assessment or SGA neonates 
<3rd percentile born within two weeks or at any stage after assessment achieved by EFW Z-score 
at 35+0 - 36+6 weeks by addition of maternal factors and either EFW growth velocity of AC growth 
velocity. Multivariable logistic regression analysis demonstrated that the only significant 
contributor to adverse perinatal outcome was maternal risk factors. Multivariable logistic 
regression analysis in the group with EFW <10th percentile demonstrated that significant 
contribution to prediction of birth of neonates with birthweight <10th and <3rd percentiles and 
adverse perinatal outcome was provided by EFW Z-score at 35+0 - 36+6 weeks, but not by AC 
growth velocity <1st decile.  
 
Conclusion: The predictive performance of EFW at 35+0 - 36+6 weeks’ gestation for birth of SGA 
neonates and adverse perinatal outcome is not improved by addition of estimated growth velocity 
between 32 and 36 weeks’ gestation. 
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INTRODUCTION 
 
Several studies have reported on prenatal diagnosis and management of small for gestational 
age (SGA) fetuses.1-13 These studies have established that: first, the predictive performance of 
the traditional method of identifying pregnancies with SGA fetuses, maternal abdominal palpation 
and serial measurements of symphysial-fundal height, is poor;1,3 second, substantially improved 
prediction of SGA is achieved by universal sonographic fetal biometry during the third trimester;8-
12 and third, about 85% of SGA neonates are born at >37 weeks’ gestation,14 and the predictive 
performance of routine ultrasonography at 36 weeks’ gestation is superior to that at 32 weeks.8,9,11  
 
Although the performance of routine ultrasonographic estimated fetal weight (EFW) at 36 weeks’ 
gestation is superior to that of other methods this requires further improvement. One approach 
aiming for such improvement in predictive performance of the 36 week’s scan is to combine EFW 
with maternal demographic characteristics and medical history; two studies reported that with the 
addition of maternal risk factors prediction of SGA neonates born at any stage after assessment 
was improved from 63% to about 67%, at screen positive rate of 10%.9,15 Further improvement in 
prediction to about 70% can be achieved with the addition of serum placental growth factor and 
uterine artery and middle cerebral artery pulsatility index.14 Another approach for improvement in 
the prediction of SGA neonates and adverse perinatal outcome provided by fetal biometry is fetal 
growth velocity; however, previous studies investigating the potential value of fetal growth velocity 
reported contradictory results.15-21 In a study of 44,043 singleton pregnancies that had undergone 
routine ultrasound examination at 19+0 - 23+6 and at 35+0 - 36+6 weeks’ gestation, we found that 
the predictive performance of EFW at 35+0 - 36+6 was not improved by addition of estimated growth 
velocity between the second and third trimesters of pregnancy.15 A possible explanation for such 
failure is the long interval between the two ultrasound examinations that defined growth velocity 
and the proximity of the second scan to delivery which would inevitably minimize the contribution 
of growth velocity to that of EFW at 35+0 - 36+6 weeks. 
 
The objective of this study is to assess the additive value of fetal growth velocity between 32 and 
36 weeks’ gestation on the performance of ultrasonographic EFW at 35+0 - 36+6 weeks’ gestation 
for prediction of SGA neonates and adverse perinatal outcome. 
 
METHODS 
 
The inclusion criteria for this study were singleton pregnancies that had undergone routine 
ultrasound examination at 35+0 - 36+6 weeks’ gestation, had a previous scan at least two weeks 
earlier at 30+0 - 34+6 weeks and delivered a non-malformed live birth or stillbirth. We excluded 
pregnancies with aneuploidies and major fetal abnormalities. The women were examined at 
King’s College Hospital, London or Medway Maritime Hospital, Gillingham, UK between October 
2013 and September 2018. We recorded maternal demographic characteristics and medical 
history and carried out the two ultrasound examinations for fetal anatomy and measurement of 
fetal head circumference (HC), AC and femur length (FL) for calculation of EFW by the Hadlock 
formula, which has been shown to be the most accurate one among 70 previously reported 
models.22,23 Gestational age was determined by the measurement of fetal crown-rump length at 
11-13 weeks or the fetal head circumference at 19-24 weeks.24,25 The ultrasound examinations 
were carried out by examiners who had obtained the Fetal Medicine Foundation certificate of 
competence in ultrasound examination for fetal abnormalities. The women gave written informed 
consent to participate in the study, which was approved by the NHS Research Ethics Committee.  
 
Patient characteristics  
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Patient characteristics recorded included maternal age, racial origin (White, Black, South Asian, 
East Asian and mixed), method of conception (natural, in vitro fertilization or use of ovulation 
induction drugs), cigarette smoking during pregnancy, medical history of chronic hypertension and 
diabetes mellitus, obstetric history including parity (parous or nulliparous if no previous 
pregnancies at > 24 weeks’ gestation), and previous pregnancy with SGA. The maternal weight 
and height were measured. 
 
Outcome measures 
 
Data on pregnancy outcome were collected from the hospital maternity records or the general 
medical practitioners of the women. The outcome measures of the study were first, delivery of 
SGA neonates with birthweight <10th and <3rd percentiles for gestational age at delivery,26 within 
two weeks and at any stage after assessment, and second, composite of adverse perinatal 
outcome defined as stillbirth, neonatal death and admission to the neonatal unit for ≥48 hours. 
 
Statistical analysis 
 
Data were expressed as median (interquartile range [IQR]) for continuous variables and n (%) for 
categorical variables. Mann-Whitney U-test and χ2-square test or Fisher’s exact test, were used 
for comparing outcome groups for continuous and categorical data, respectively. Significance was 
assumed at 5%. 
 
In the dataset of 14,497 singleton pregnancies with paired measurements of fetal biometry at 30+0 
- 34+6 and 35+0 - 36+6 weeks’ gestation, the observed measurements of AC and EFW were 
expressed as Z-scores for gestational age.25,26 Fetal growth velocity was defined as the difference 
in AC Z-scores and EFW Z-scores between the two ultrasound scans divided by the time interval 
in days between them. Univariable and multivariable regression analysis was carried out to 
determine whether the addition of AC and EFW growth velocity and maternal factors to the EFW 
Z-score at 35+0 - 36+6 weeks’ gestation improved the performance of screening for first, SGA 
neonates <10th and <3rd percentile delivering within two weeks and at any stage after assessment, 
and second, adverse perinatal outcome. In prediction of the adverse outcomes, we assumed the 
relationship between the dependent and independent variables to be linear as the evaluation of 
growth velocity was only between gestational window of 32 and 36 weeks’ gestation. The a priori 
risk for SGA based on maternal factors was derived from a dataset of 124,443 singleton 
pregnancies at 11+0 - 13+6 weeks’ gestation using multivariable logistic regression analysis with 
backward stepwise elimination to determine which of the factors among maternal characteristics 
and medical and obstetric history had a significant contribution in predicting SGA <10th.14 
Regression analysis was also carried out in the group with EFW <10th percentile to determine 
whether EFW Z-score at 35+0 - 36+6 weeks’ gestation and AC growth velocity <1st decile had a 
significant contribution in the prediction of first, SGA neonates <10th  and <3rd percentile delivering 
at any stage after assessment, and second, adverse perinatal outcome. The performance of 
screening was determined by receiver operating characteristic (ROC) curves. We estimated 
detection rates (DR) with 95% confidence intervals (CI) for fixed screen positive rate of 10% and 
screen positive rates (95% CI) for fixed DRs of 85%, 90% and 95%. 
 
The statistical software package SPSS 24.0 (IBM SPSS Statistics for Windows, Version 24.0, 
Armonk, NY: IBM Corp; 2016) and Medcalc (Medcalc Software, Mariakerke, Belgium) were used 
for data analyses. 
 
RESULTS 
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Patient characteristics 
 
During the study period 44,043 singleton pregnancies had undergone routine ultrasound 
examination at 35+0 - 36+6 weeks’ gestation. Search of our fetal database identified 14,497  of 
these 44,043 pregnancies that had undergone an additional ultrasound examination at least two 
weeks earlier at 30+0 - 34+6 weeks. The indications for the ultrasound scan at 30+0 - 34+6 weeks 
included: (a) high risk of preeclampsia (PE) and / or SGA because of abnormal screening results 
in the first or second trimester of pregnancy, such as low serum PAPP-A, high uterine artery PI or 
single umbilical artery (27.8%); (b) previous pregnancy complications, such as perinatal death, 
abruption, PE and / or SGA (11.4%); (c) maternal medical disorders, such as chronic 
hypertension, antiphospholipid syndrome, diabetes mellitus or hypothyroidism (11.7%); (d) 
pregnancy complications, such as PE, gestational diabetes mellitus, or cholestasis (9.1%); (e) 
small or big symphysial-fundal height (11.9%), increased maternal age or weight (9.0%); reduced 
fetal movements (7.0%); (f) minor fetal defects, such as mild ventriculomegaly, or mild 
hydronephrosis (5.0%); (g) low lying placenta and / or antepartum hemorrhage (6.2%); and (h) 
increased risk of preterm birth due to abdominal pain, reduced cervical length or history of 
previous preterm birth (0.9%).   
 
The characteristics of the study population of 14,497 pregnancies are shown in Table 1. In the 
group with SGA neonates, compared to those with birthweight ≥10th percentile, the median 
maternal age, weight and height, EFW Z-score at both visits and birthweight z-score were lower, 
more women were of non-White racial origin, were smokers, were nulliparous or parous with 
previous affected pregnancy by SGA, and less women had diabetes mellitus type 1 or type 2. The 
incidence of adverse perinatal outcome was significantly higher in the SGA than in the non-SGA 
group (12.8% vs. 8.6%; p<0.001).  
 
Prediction of SGA neonates  
 
Multivariable logistic regression analysis demonstrated that significant contributors to prediction 
of SGA neonates were EFW Z-score at 35+0 - 36+6 weeks’ gestation, fetal growth velocity by either 
AC or EFW Z-scores and maternal risk factors (Table 2). The area under the receiver operating 
characteristic curves (AUROC) for prediction of SGA neonates <10th percentile born within two 
weeks of assessment achieved by EFW Z-score at 35+0 - 36+6 weeks were not significantly 
improved by addition of EFW growth velocity and maternal risk factors (0.938, 0.928 - 0.947 vs. 
0.941, 0.932 - 0.950; p=0.061) (Table 3, Figure 1). Similarly, there were no statistically significant 
differences in DR, at 10% screen positive rate, in screening with and without the addition of EFW 
growth velocity and maternal risk factors (Table 3); similar results were obtained when growth 
velocity was defined by AC Z-score. There was no significant improvement in AUROC and DR, at 
10% screen positive rate, for prediction of SGA neonates <10th percentile born at any stage after 
assessment or SGA neonates <3rd percentile born within two weeks or at any stage after 
assessment achieved by EFW Z-score at 35+0 - 36+6 weeks by addition of maternal risk factors 
and either EFW growth velocity of AC growth velocity.  
 
The screen positive rates necessary to achieve prediction of 85%, 90% and 95% of SGA neonates 
born within two weeks and at any stage after assessment at 35+0 – 36+6 weeks’ gestation are 
shown in Table 4. For a desired 90% prediction of SGA neonates <10th percentile born at any 
stage after assessment the necessary screen positive rate would be 30.7% (95% CI 29.9 - 31.5%) 
in screening by EFW Z-score at 35+0 - 36+6 weeks and 29.8% (95% CI 29.0 - 30.6%) in screening 
by EFW Z-score, AC growth velocity and maternal risk factors. 
 
Prediction of adverse perinatal outcome  
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The incidence of adverse perinatal outcome in the study population was 9.2% (1,336/14,497). 
The contribution of SGA neonates with birthweight <10th percentile to adverse perinatal outcome 
was 21.7% (290/1,336). Multivariable logistic regression analysis in the whole population 
demonstrated that the only significant contributor to adverse perinatal outcome was maternal risk 
factors (Table 2).  
 
Prediction in the group with EFW <10th percentile 
 
Multivariable logistic regression analysis in the group with EFW <10th percentile demonstrated 
that significant contribution to prediction of birth of neonates with birthweight <10th and <3rd 
percentiles and adverse perinatal outcome was provided by EFW Z-score at 35+0 - 36+6 weeks, 
but not by AC growth velocity <1st decile (Table 5).  
 
DISCUSSION 
 
Main findings of the study 
 
The findings of this study demonstrate that although significant contributors to prediction of SGA 
neonates were EFW Z-score at 35+0 - 36+6 weeks’ gestation, fetal growth velocity between 32 and 
36 weeks by either AC or EFW Z-scores and maternal risk factors, the predictive performance of 
EFW was not improved by the addition of growth velocity and maternal risk factors. The incidence 
of adverse perinatal outcome was higher in SGA than in non-SGA neonates (12.8% vs. 8.6%), 
but about 80% of adverse perinatal events occurred in non-SGA neonates. The only significant 
contributor to adverse perinatal outcome was maternal risk factors. Multivariable logistic 
regression analysis in the group with EFW <10th percentile demonstrated that significant 
contribution to prediction of birth of SGA neonates and adverse perinatal outcome was provided 
by EFW Z-score at 35+0 - 36+6 weeks, but not by AC growth velocity <1st decile.  
 
Comparison with findings from previous studies 
 
Previous studies have investigated the effect of fetal growth velocity on prediction of first, birth of 
SGA neonates and second, adverse perinatal outcome. In relation to prediction of birth of SGA 
neonates, our finding that the performance of EFW is not improved by the addition of growth 
velocity is consistent with the results of previous studies. Tarca et al., examined 
3,440 pregnancies and reported that serial fetal biometry did not improve the prediction of SGA 
neonates provided by the last EFW before delivery alone.16 Caradeux et al., examined 2,696 
pregnancies at 22 and 32 weeks’ gestation and reported that the growth velocity in AC between 
22 and 32 weeks did not improve the prediction of SGA neonates provided by AC at 32 weeks.17 
Ciobanu et al., examined 44,043 singleton pregnancies that had undergone routine ultrasound 
examination at 19+0 - 23+6 and at 35+0 - 36+6 weeks’ gestation and reported that the predictive 
performance for SGA neonates provided by EFW in the third trimester is not improved by addition 
of estimated growth velocity between the second and third trimesters of pregnancy.15  
 
In relation to prediction of adverse perinatal outcome, previous studies examined the effect of 
growth velocity or conditional growth in SGA fetuses rather than in the total population. Sovio et 
al., reported that in 562 SGA fetuses with EFW <10th percentile during a third trimester scan, low 
growth velocity below the 1st decile in fetal AC between 20 weeks’ gestation and the last scan 
before delivery had a higher prevalence of adverse perinatal outcome, compared to those without 
such a degree of decrease in growth velocity (15.7% vs. 10.3%; p=0.01); however, the authors 
did not present evidence that growth velocity improved the performance of screening for adverse 
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perinatal outcome achieved by EFW percentile alone.12 Karlsen et al., performed serial ultrasound 
scans in 211 pregnancies with suspected SGA fetuses and reported that growth velocity improved 
the prediction of adverse perinatal outcome provided by cross sectional measurements of fetal 
biometry.18 In contrast, Cavallaro et al., reported that in 235 SGA fetuses diagnosed at 36-38 
weeks’ gestation low growth velocity in fetal AC between 19-21 and 36-38 weeks did not improve 
the prediction of adverse perinatal outcome provided by EFW and cerebroplacental ratio at 36-38 
weeks (AUROC 0.741 vs 0.669; p=0.110).19 Similarly, Hutcheon et al., used the EFW in 9,239 
singleton pregnancies undergoing routine ultrasound examination at 32-33 weeks’ gestation to 
predict birthweight and reported that deviations between expected and observed birthweights, 
attributed to varying growth velocities between the scan and delivery, did not improve the 
prediction of adverse outcome of SGA neonates provided by their birthweight percentile alone.20 
Caradeux et al., examined longitudinally 472 SGA fetuses diagnosed >32 weeks’ gestation and 
reported that in subsequent scans growth velocity in EFW did not improve the prediction of 
adverse perinatal outcome provided by EFW, uterine artery pulsatility index and cerebroplacental 
ratio recorded in the last scan before delivery.21 
 
Implications for clinical practice 
 
Several studies have reported first, how best to monitor and deliver SGA neonates,2,5-7 second, 
that about 85% of SGA neonates are born at ≥37 weeks’ gestation and third, the best prediction 
of SGA neonate is achieved by routine ultrasound examination at 36 week’s gestation.8,9,11,12,14 
This findings of this study have highlighted the necessity to improve the performance of the 36 
weeks’ assessment in the prediction of both birth of SGA neonates and adverse perinatal outcome 
and have demonstrated that these goals cannot be achieved by addition of fetal growth velocity 
between 32 and 36 weeks’ gestation to EFW at 36 weeks. 
 
Strengths and limitations of the study 
 
The strengths of this screening study for SGA neonates are first, examination of a large population 
of pregnant women attending for assessment of fetal growth and wellbeing at both 30+0 - 34+6  and 
35+0 - 36+6 weeks’ gestation, second, trained sonographers that carried out fetal biometry 
according to a standardized protocol and use of a widely used model for calculation of EFW22 
which has been shown to be the most accurate one among 70 previously reported models,23 third, 
use of the Fetal Medicine Foundation fetal and neonatal references ranges which have a common 
median,26 and fourth, use of well accepted indicators for adverse perinatal outcome. 
 
A potential limitation of the study is the selection of patients undergoing the two ultrasound 
examinations. During the study period we offered routine ultrasound examinations at 11+0 - 13+6, 
19+0 - 23+6 and at 35+0 - 36+6 weeks’ gestation, whereas a scan at 30+0 - 34+6 weeks was offered 
only to women considered to be at increased risk of fetal growth disturbances or adverse outcome 
based on their demographic characteristics, medical history, results of first or second trimester 
screening for preeclampsia, small or large symphysial-fundal height and pregnancy 
complications. As a consequence of such preselection the predictive performance of EFW at 35+0 
- 36+6 weeks’ gestation for SGA neonates and adverse perinatal outcome may not be the same 
as in an unselected population. However, the objective of the study was to examine the effect of 
growth velocity on the performance of the EFW at 35+0 - 36+6 and in this respect the results are 
valid. A limitation of the study is the assumption of the linear relationship between dependent and 
independent variables in regression analysis. Linear relationship was assumed as we examined 
the growth velocity in the narrow gestational window between 32 and 36 weeks’ gestation. 
 
Conclusions 
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The predictive performance of EFW at 35+0 - 36+6 weeks’ gestation for birth of SGA neonates and 
adverse perinatal outcome is not improved by addition of estimated growth velocity between 32 
and 36 weeks’ gestation. The incidence of adverse perinatal outcome is higher in SGA than in 
non-SGA neonates, but only about one-fifth of adverse perinatal events are found in association 
with SGA neonates. Future studies will investigate the potential improvement in prediction of 
adverse perinatal outcome by biomarkers of impaired placentation at the time of the 36 weeks’ 
assessment.   
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FIGURE LEGENDS 
 
Figure 1. Receiver operating characteristics curves of maternal risk factors (black curve), 
estimated fetal weight at 35+0 - 36+6 weeks’ gestation (blue curve), estimated fetal weight growth 
velocity (green curve), and the combination of the three (red curve) in the prediction of small for 
gestational age neonates with birth weight below the 10th percentile delivering within two weeks 
(left) and at any time (right) from assessment. 
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Table 1- Maternal and pregnancy characteristics in pregnancies delivering small for gestational 
age neonates <10th percentile and those without. 
 
 
BW = birth weight; GA = gestational age; EFW = estimated fetal weight; IQR = interquartile range; 
SGA = small for gestational age 
  
  
Characteristic 
BW ≥10th percentile 
(n=12,216) 
BW <10th percentile 
(n=2,281) 
P-value 
Maternal age in years, median (IQR) 32.2 (27.8-36.1) 31.2 (26.5-35.3) <0.001 
Maternal weight in Kg, median (IQR) 81.6 (72.0-94.3) 74.0 (65.6-85.0) <0.001 
Maternal height in cm, median (IQR) 165 (160-169) 163 (158-167) <0.001 
Racial origin    
   White, n (%) 8,917 (73.0) 1,428 (62.6) <0.001 
   Black, n (%) 2,142 (17.5) 515 (22.6) <0.001 
   South Asian, n (%) 573 (4.7) 214 (9.4) <0.001 
   East Asian, n (%) 228 (1.9) 51 (2.2) 0.238 
   Mixed, n (%) 356 (2.9) 73 (3.2) 0.459 
Cigarette smoker, n (%) 942 (7.7) 337 (14.8) <0.001 
Conception    
   Natural, n (%) 11,693 (95.7) 2,190 (96.0)  
   Ovulation drugs, n (%) 71 (0.6) 14 (0.6) 0.852 
   In vitro fertilization, n (%) 452 (3.7) 77 (3.4) 0.448 
Medical conditions    
   Chronic hypertension, n (%) 383 (3.1) 71 (3.1) 0.955 
   Diabetes mellitus type 1, n (%) 161 (1.3) 1 (0.04) <0.001 
   Diabetes mellitus type 2, n (%) 215 (1.8) 22 (1.0) 0.006 
Past obstetric history    
   Nulliparous, n (%) 4,848 (39.7) 1,154 (50.6) <0.001 
   Parous with prior SGA, n (%) 1,218 (10.0) 529 (23.2) <0.001 
   Parous without prior SGA, n (%) 6,150 (50.3) 598 (26.2) <0.001 
GA at screening at 30+0 – 34+6 weeks, median (IQR)  32.3 (31.9-32.6) 32.3 (31.9-32.7) <0.001 
EFW Z-score at 30+0 – 34+6 weeks, median (IQR) 0.21 (-0.43-0.89) -1.11 (-1.79- -0.51) <0.001 
AC Z-score at 30+0 – 34+6 weeks, median (IQR) 0.04 (-0.40-0.50) -0.76 (-1.19- -0.37) <0.001 
GA at screening at 35+0-36+6 weeks, median (IQR)  36.1 (35.9-36.4) 36.1 (35.9-36.4) 0.020 
EFW Z-score at 35+0-36+6 weeks, median (IQR) 0.17 (-0.47-0.82) -1.44 (-2.14- -0.78) <0.001 
AC Z-score at 35+0 – 36+6 weeks, median (IQR) -0.06 (-0.56-0.47) -1.18 (-1.17- -0.70) 0.001 
GA at delivery in weeks, median (IQR) 39.6 (38.9-40.6) 39.1 (38.0-40.1) <0.001 
Birthweight Z-score, median (IQR) 0.07 (-0.53-0.71) -1.79 (-2.25- -1.51) <0.001 
Birthweight in grams, median (IQR) 3422 (3155-3725) 2655 (2440-2820) <0.001 
Adverse perinatal outcome, n (%) 1,046 (8.6) 290 (12.8) <0.001 
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Table 2. Multivariable logistic regression analysis in prediction of small for gestational age 
neonates <10th and <3rd percentiles and adverse perinatal outcome from maternal risk factors, 
estimated fetal weight Z-score at 35+0 – 36+6 weeks’ gestation and estimated fetal weight growth 
velocity (top table) or abdominal circumference growth velocity (bottom table). 
 
Characteristic 
Univariable Multivariable 
OR (95% CI) P value OR (95% CI) P value 
Birthweight <10th percentile     
Maternal risk factors 13.55 (11.49-15.99) <0.001 5.77 (4.71-7.07) <0.001 
EFW z-score 0.17 (0.16-0.18) <0.001 0.17 (0.16-0.18) <0.001 
EFW growth velocity 3.01e-7 (5.44e-8-2.01e-6) <0.001 1.25e3 (1.19e2-1.32e4) <0.001 
Birthweight <3rd percentile     
Maternal risk factors 13.80 (10.94-17.40) <0.001 4.46 (3.37-5.92) <0.001 
EFW z-score 0.17 (0.15-0.18) <0.001 0.16 (0.15-0.18) <0.001 
EFW growth velocity 3.43e-8 (3.28e-9-3.60e-7) <0.001 7.09e3 (3.16e2-1.59e5) <0.001 
Adverse perinatal outcome     
Maternal risk factors 0.66 (0.50-0.87) 0.004 0.66 (0.50-0.87) 0.004 
EFW z-score 0.97 (0.91-1.03) 0.282   
EFW growth velocity 0.48 (0.02-11.09) 0.645   
 
Characteristic 
Univariable Multivariable 
OR (95% CI) P value OR (95% CI) P value 
Birthweight <10th percentile     
Maternal risk factors 13.55 (11.49-15.99) <0.001 5.74 (4.69-7.03) <0.001 
EFW z-score 0.17 (0.16-0.18) <0.001 0.17 (0.15-0.18) <0.001 
AC growth velocity 8.04e-12 (9.33e-13-6.92e-11) <0.001 5.80e3 (2.85e2-1.18e5) <0.001 
Birthweight <3rd percentile     
Maternal risk factors 13.80 (10.94-17.40) <0.001 4.46 (3.37-5.92) <0.001 
EFW z-score 0.17 (0.15-0.18) <0.001 0.16 (0.15-0.18) <0.001 
AC growth velocity 1.76e-13 (9.09e-15-3.40e-12) <0.001 3.10e3 (0.58e2-1.64e5) <0.001 
Adverse perinatal outcome     
Maternal risk factors 0.66 (0.50-0.87) 0.004 0.66 (0.50-0.87) 0.004 
EFW z-score 0.97 (0.91-1.03) 0.282 - - 
AC growth velocity 15.18 (0.37-626.41) 0.152 - - 
 
EFW = estimated fetal weight; AC = Abdominal circumference; OR = odds ratio; CI = confidence 
interval; SGA = small for gestational age 
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Table 3. Performance of prediction of small for gestational age neonates with birth weight <10th, 
and <3rd percentile delivering within two weeks and at any stage after screening at 35+0 – 36+6 
weeks’ gestation from maternal risk factors, estimated fetal weight Z-score at 35+0 – 36+6 weeks’ 
gestation and estimated fetal weight growth velocity (top table) or abdominal circumference 
growth velocity (bottom table). 
 
 
 
AUROC = area under the receiver operating characteristic curves; CI = confidence interval; EFW 
= estimated fetal weight; AC = abdominal circumference; SGA = small for gestational age; DR = 
detection rate; SPR = screen positive rate  
  
Screening test 
Birthweight <10th percentile Birthweight  <3rd percentile 
AUROC curve 
(95% CI) 
DR at 10% SPR 
% (95% CI) 
AUROC curve 
(95% CI) 
DR at 10% SPR 
% (95% CI) 
SGA within 2 weeks     
EFW Z-score at 35+0 - 36+6 weeks 0.938 (0.928, 0.947) 80.7 (77.6, 83.9) 0.943 (0.934, 0.952) 80.5 (77.2, 83.7) 
Maternal risk factors  0.696 (0.673, 0.718) 29.1 (26.5, 32.4) 0.691 (0.663, 0.718) 28.1 (25.2, 31.6) 
EFW growth velocity 0.670 (0.645, 0.694) 31.3 (28.4, 34.7) 0.694 (0.664, 0.725) 35.9 (32.3, 38.8) 
EFW Z-score + EFW growth velocity 
+ maternal risk factors 
0.941 (0.932, 0.950) 82.5 (79.4, 85.3) 0.944 (0.935, 0.953) 79.2 (76.3, 82.6) 
SGA at any stage     
EFW Z-score at 35+0 - 36+6 weeks 0.891 (0.885, 0.898) 65.3 (63.0, 67.7) 0.920 (0.913, 0.928) 73.3 (70.2, 76.1) 
Maternal risk factors  0.709 (0.697, 0.720) 31.1 (28.6, 33.1) 0.712 (0.696, 0.729) 32.4 (29.7, 35.9) 
EFW growth velocity 0.613 (0.600, 0.626) 21.2 (18.6, 24.4) 0.636 (0.617, 0.654) 25.4 (22.6, 28.7) 
EFW Z-score + EFW growth velocity 
+ maternal risk factors 
0.902 (0.896, 0.908) 69.3 (66.8, 72.4) 0.927 (0.920, 0.934) 75.2 (72.4, 78.6) 
Screening test 
Birthweight <10th percentile Birthweight  <3rd percentile 
AUROC curve 
(95% CI) 
DR at 10% SPR 
% (95% CI) 
AUROC curve 
(95% CI) 
DR at 10% SPR 
% (95% CI) 
SGA within 2 weeks     
EFW Z-score at 35+0 - 36+6 weeks 0.938 (0.928, 0.947) 80.7 (77.6, 83.9) 0.943 (0.934, 0.952) 80.5 (77.2, 83.7) 
Maternal risk factors  0.696 (0.673, 0.718) 29.1 (26.5, 32.4) 0.691 (0.663, 0.718) 28.1 (25.2, 31.6) 
AC growth velocity 0.722 (0.699, 0.745) 35.1 (32.0, 38.4) 0.747 (0.719, 0.775) 38.0 (35.1, 41.3) 
EFW Z-score + AC growth velocity 
+ maternal risk factors 
0.941 (0.932, 0.950) 81.9 (78.3, 84.7) 0.944 (0.935, 0.954) 80.2 (77.7, 83.8) 
SGA at any stage     
EFW Z-score at 35+0 - 36+6 weeks 0.891 (0.885, 0.898) 65.3 (63.0, 67.7) 0.920 (0.913, 0.928) 73.3 (70.2, 76.1) 
Maternal risk factors  0.709 (0.697, 0.720) 31.1 (28.6, 33.1) 0.712 (0.696, 0.729) 32.4 (29.7, 35.9) 
AC growth velocity 0.659 (0.647-0.672) 24.4 (21.3, 27.7) 0.689 (0.671-0.706) 30.0 (27.1, 33.6) 
EFW Z-score + AC growth velocity 
+ maternal risk factors 
0.902 (0.896, 0.908) 69.2 (66.7, 72.3) 0.926 (0.919, 0.934) 75.9 (73.0, 78.8) 
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Table 4. Screen positive rate necessary to achieve prediction of 85%, 90% and 95% of small for 
gestational age neonates delivering within two weeks and at any stage after assessment at 35+0 – 36+6 
weeks’ gestation. 
 
CI = confidence interval; SGA = small for gestational age; EFW = estimated fetal weight; AC = 
abdominal circumference. 
 
  
Screening test 
Screen positive rate for detection rate of: 
85% (95% CI) 90% (95% CI) 95% (95% CI) 
SGA within 2 weeks  
SGA <10th percentile  
EFW Z-score at 35+0 - 36+6 weeks 16.6 (12.1, 15.2) 18.9 (17.2, 20.7) 26.4 (24.4, 28.4) 
EFW Z-score + EFW growth velocity + maternal risk factors 12.0 (10.6, 13.6) 17.2 (15.6, 19.0) 27.1 (25.1, 29.2) 
EFW Z-score + AC growth velocity + maternal risk factors 12.6 (11.1, 14.2) 17.7 (16.0, 19.5) 27.5 (25.5, 29.5) 
SGA <3rd percentile    
EFW Z-score at 35+0 - 36+6 weeks 13.4 (12.0, 14.9) 16.7 (15.1, 18.3) 22.0 (20.3, 23.8) 
EFW Z-score + EFW growth velocity + maternal risk factors 13.1 (11.7, 14.6) 16.1 (14.6, 17.7) 20.4 (18.7, 22.1) 
EFW Z-score + AC growth velocity + maternal risk factors 13.1 (11.7, 14.6) 15.4 (13.9, 16.9) 20.1 (18.5, 21.9) 
SGA at any stage  
SGA <10th percentile  
EFW Z-score at 35+0 - 36+6 weeks 21.2 (23.4, 25.0) 30.7 (29.9, 31.5) 43.0 (42.1, 43.9) 
EFW Z-score + EFW growth velocity + maternal risk factors 22.2 (21.4, 22.9) 29.8 (29.0, 30.6) 40.0 (39.1, 40.8) 
EFW Z-score + AC growth velocity + maternal risk factors 22.4 (21.6, 23.1) 29.4 (28.5, 30.2) 40.2 (39.3, 41.2) 
SGA <3rd percentile    
EFW Z-score at 35+0 - 36+6 weeks 17.7 (17.1, 18.4) 23.1 (22.4, 23.9) 32.8 (32.0, 33.6) 
EFW Z-score + EFW growth velocity + maternal risk factors 16.2 (15.6, 16.8) 20.8 (20.1, 21.5) 31.0 (30.2, 31.8) 
EFW Z-score + AC growth velocity + maternal risk factors 16.2 (15.6, 16.8) 21.3 (20.6, 22.0) 31.0 (30.3, 21.8) 
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Table 5. Prediction of adverse perinatal outcomes from multivariable logistic regression analysis 
demonstrating the contribution of abdominal circumference growth velocity <1st decile, in addition to 
the estimated fetal weight Z-score in pregnancies with estimated fetal weight below the 10th percentile 
at 35+0 – 36+6 weeks’ gestation. 
 
Variable 
SGA <10th percentile 
OR (95% CI) 
SGA <3rd percentile 
OR (95% CI) 
Adverse perinatal outcome 
OR (95% CI) 
EFW Z-score at 
35+0 - 36+6 weeks 
0.20 (0.16, 0.24) 
p<0.001 
0.23 (0.19, 0.28) 
p<0.001 
0.50 (0.43, 0.59) 
p<0.001 
AC growth velocity 
<1st decile 
0.84 (0.66, 1.05) 
P=0.123 
0.98 (0.78, 1.24) 
P=0.884 
1.15 (0.86, 1.55) 
P=0.343 
 
EFW = estimated fetal weight; AC = abdominal circumference; OR = odds ratio; CI = confidence 
interval; 
 
 
